Micron’s stock is leading the market right now for one clear reason: AI demand has changed the value of memory, and investors are finally reacting. Over the pastMicron’s stock is leading the market right now for one clear reason: AI demand has changed the value of memory, and investors are finally reacting. Over the past

Micron shares up nearly 250% in the last year, riding on AI-driven memory demand

2026/01/07 21:41
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Micron’s stock is leading the market right now for one clear reason: AI demand has changed the value of memory, and investors are finally reacting.

Over the past 12 months, Micron stock has surged by 237%, putting it ahead of nearly every large-cap tech name.

UBS turned bullish on Micron this week when it repeated its buy rating on Micron and raised its price target to $400 from $300, which is a 16% rally from the price as of Tuesday’s close.

AI demand is tightening supply and transforming how investors trade Micron’s stock

UBS analyst Timothy Arcuri said in a note on Monday that their revision is thanks mainly to all those investor meetings with Micron management, where executives said they believe the current memory cycle will last longer than past ones.

“We still believe investors are underappreciating the degree to which AI has fundamentally made memory, DRAM in particular, a more strategic asset,” Timothy wrote.

Timothy said supply remains constrained. According to UBS, Micron is currently able to meet only 50% to 75% of demand from its largest customers. He said AI workloads have forced customers to stop treating memory like a low-cost commodity. Memory is now seen as a strategic input, which has changed how companies plan purchases and secure long-term supply.

“Severe supply shortages supportive of an extended and durable memory upcycle,” Timothy wrote.

He also said the pricing setup has changed. In the pre-AI period, memory suppliers earned little extra for higher performance products because memory was just another system part. That is no longer the case.

“Suppliers are now getting paid for best-in-class performance as memory has become a key differentiator within hardware systems,” Timothy wrote, pointing to Nvidia’s Blackwell and Blackwell Ultra platforms.

He added that DRAM content growth inside AI servers is still not fully priced in by the market. Micron believes DRAM offers better value than NAND because it allows more customization and higher product quality.

The stock’s strength has also drawn attention in the options market. Most short-dated options expire worthless and lose value fast due to time decay. Many traders sell these options to capture that decay, but that strategy comes with short gamma risk, meaning sharp price swings can hit profits quickly. Longer-dated buy-writes and defined-risk call-spread risk reversals reduce that exposure, especially in stocks with high long-term implied volatility.

We took a look at a 2025 situation to explain this setup, specifically when Nvidia surged by just over 30% from January 3, 2025, to January 2, 2026.

A long-dated call spread risk reversal tied to Nvidia slightly lagged the stock but showed much lower volatility, per data from Bloomberg Terminal.

Want your project in front of crypto’s top minds? Feature it in our next industry report, where data meets impact.

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09